SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine（Abogen）

新型冠状病毒BA.4 /5变体mRNA疫苗（Vero细胞）（艾博生物）

Report date: 2026/05/13 09:17:06

Base Information

Drug NameSARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine（Abogen）

Drug Alias NameABO1020ABO-1020

ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Application > Prophylactic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryPakistanPhilippinesUnited Arab Emirates +[4]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesAbogen Biosciences Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesAbogen Biosciences Co Ltd

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A